Sign Up to like & get
recommendations!
0
Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2399
Abstract: Purpose: We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784). Patients and Methods: Adults with relapsed/refractory B-cell precursor CD22-positive (by local…
read more here.
Keywords:
ozogamicin versus;
cd22 positivity;
inotuzumab ozogamicin;
cd22 ... See more keywords